Swedish Research Council: Macchiarini, Karolinska Skipped Ethical Review

The federal agency publishes a brief note alleging another ethical breach by former Karolinska Institute researcher Paolo Macchiarini.

Written byBob Grant
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, IJNMIS01A Swedish law in place since January 2004 regarding research conducted on human beings (including living people, cadavers, biological material from people, and sensitive personal information) requires that investigators conducting such work apply for ethical review. According to Anna Hörnlund, chief legal counsel at the Swedish Research Council, neither former Karolinska Institute researcher Paolo Macchiarini nor his former institution submitted an application before conducting such research. “The Swedish Research Council considers Paolo Macchiarini's activities to be research conducted in human beings,” Hörnlund wrote in The Lancet last week (April 30).

Also last week (April 28), the Karolinska Institute announced that it is investigating concerns about Macchiarini and colleagues’ 2015 Respiration paper on the administration of an experimental cellular treatment on a patient with acute respiratory distress syndrome. “I received the case on my desk last week. We have analyzed it and will demand answers from the researchers involved,” Henrik Grönberg, pro-vice-chancellor of the Karolinska Institute, said in the statement. “After that, we will decide if we will submit the matter for external review.”

Some of Macchiarini’s coauthors on a 2011 The Lancet paper last month asked to have their names removed from that study. The Karonliska Institute terminated its contract with Macchiarini in March.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer. Before joining the team, he worked as a reporter at Audubon and earned a master’s degree in science journalism from New York University. In his previous life, he pursued a career in science, getting a bachelor’s degree in wildlife biology from Montana State University and a master’s degree in marine biology from the College of Charleston in South Carolina. Bob edited Reading Frames and other sections of the magazine.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies